We sat down with Xiaojun Liu, director of AAV process development at ReciBioPharm, to discuss the growing need for carefully designed platforms to deliver safe and cost-effective AAV therapies to patients at pace.
Quest Diagnostics, a provider of diagnostic information services, has announced that its AAVrh74 ELISA assay (CDx) has been granted breakthrough device designation from the U.S. Food and Drug Administration (FDA).
Chameleon Biosciences, a Berkeley-based biotech aiming to enable safer and more effective gene therapies, has won the Immunomodulatory Solution of the Year in the Biotech Breakthrough Awards, run by the Tech Breakthrough organization.
Rocket Pharmaceuticals, a late-stage, clinical biotech advancing a pipeline of genetic therapies for rare childhood disorders, will acquire Renovacor: helping it strengthen its position in AAV-based cardiac gene therapy.
The Cell and Gene Therapy Catapult (CGT Catapult) and the UK Dementia Research Institute (UK DRI) have announced a collaboration to accelerate clinical development of adeno-associated virus (AAV) based gene therapies for dementia.
AskBio, a gene therapy company owned and operated as a subsidiary of Bayer AG, and Touchlight, a biotech focused on enzymatic DNA production, have announced a revised structure to their former joint venture, Touchlight AAV.
There is a healthy appetite for continued investment in gene therapy, in new modalities and more indications, says an industry insider as he reflected on the prospects for the US gene therapy sector next year.
Charles River and ATEM Structural Discovery (ATEM) are collaborating to provide access to cryo-electron microscopy (cryo-EM), a technique that visualizes molecules and proteins in atomic resolution to determine their 3D shape.
LEXEO Therapeutics, a clinical-stage gene therapy company, is partnering with CDMO, Fujifilm Diosynth Biotechnologies (FDB), to support the development and manufacturing of its AAV-mediated gene therapies.
This month sees the launch of a new gene therapy player, Opus Genetics, a company backed and spun out by leading patient group Foundation Fighting Blindness’ venture arm, the Retinal Degeneration Fund (RD Fund).
Synthetic DNA vector producer, Touchlight, has announced the extension of its fundraising round to a current aggregate total of US$125m (£92m). The financing was led by Bridford Investments Limited and Novator Partners.